Transfers of Value to Healthcare Professionals and Healthcare Organisations

Bayer is committed to fostering transparency in its financial relations with healthcare professionals and healthcare organisations and believes that it creates trust in the innovative pharmaceutical industry.

Collaborative Research Benefits Patients and Society

The collaboration between the pharmaceutical industry and both healthcare professionals and healthcare organisations has delivered numerous innovative medicines and changed the way many diseases impact our lives. We at Bayer believe this collaboration is key to achieving better outcomes for the patients we strive to help.

Pharmaceutical Industry – Healthcare Professionals: A Highly Regulated Relationship

When collaborating with medical experts, we comply with existing laws and regulations that clearly outline the interaction between industry and healthcare professionals, e.g. healthcare laws and industry codes. Additionally, these rules are amended by different transparency regulations, such as the Sunshine Act in the US, the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code (http://transparency.efpia.eu/ )in Europe, and more locally the Irish Pharmaceutical Healthcare Association (IPHA) Disclosure Code (http://www.ipha.ie/alist/publications.aspx?article=f8f9c1e9-344a-468c-b7d2-dc83530513b1). We fully respect the independence and integrity of these professionals.

What the EFPIA Disclosure Code is About (http://transparency.efpia.eu/)
Implementing the EFPIA Disclosure Code

 

As a member of EFPIA and in line with our company values we fully endorse the EFPIA Disclosure Code. In Ireland, the implementation of this Code is carried out in accordance with the IPHA Disclosure Code. In Ireland, Bayer will disclose payments as well as benefits in kind to healthcare professionals and healthcare organisations on an online platform managed by IPHA.